MUSTANG BIO, INC.

Profile

Company Names

MUSTANG BIO, INC.

Addresses

377 PLANTATION STREET, WORCESTER, MA 01605

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014

Phone Numbers

7816524500
7816524507

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2015

State Incorporated:

DELAWARE

Total Amount Raised:

$240,209,732.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2024-06-19 
$2,513,139.00 
$2,513,139.00 
$0.00 
 
8
2023-10-26 
$4,742,942.00 
$4,742,942.00 
$0.00 
Equity 
7
2017-03-31 
$416,000.00 
$416,000.00 
$0.00 
Equity 
6
2017-01-31 
$94,585,711.00 
$100,000,000.00 
$5,414,289.00 
Equity 
5
2016-12-29 
$39,096,680.00 
$70,000,000.00 
$30,903,320.00 
Equity 
4
2016-12-12 
$34,987,081.00 
$70,000,000.00 
$35,012,919.00 
Equity 
3
2016-11-30 
$31,886,581.00 
$70,000,000.00 
$38,113,419.00 
Equity 
2
2016-10-25 
$19,535,184.00 
$70,000,000.00 
$50,464,816.00 
Equity 
1
2016-09-30 
$12,446,414.00 
$70,000,000.00 
$57,553,586.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ADAM 
J. 
CHILL 
DIRECTOR
KINGSBROOK OPPORTUNITIES LP   |  KINGSBROOK OPPORTUNITIES FUND LTD   |  CB PHARMA ACQUISITION CORP.   |  MUSTANG BIO, INC.
NEIL 
 
HERSKOWITZ 
DIRECTOR
MANHATTAN PHARMACEUTICALS INC   |  ALACRITY BIOSCIENCES INC   |  CB PHARMA ACQUISITION CORP.   |  CHECKPOINT THERAPEUTICS, INC.   |  MUSTANG BIO, INC.   |  AVENUE THERAPEUTICS, INC.   |  JOURNEY MEDICAL CORP
MANUEL 
B. 
LITCHMAN, M.D. 
EXECUTIVE OFFICER, DIRECTOR
MUSTANG BIO, INC.
MANUEL 
S. 
LITCHMAN, M.D. 
EXECUTIVE OFFICER, DIRECTOR
MUSTANG BIO, INC.
ELIOT 
 
LURIER 
EXECUTIVE OFFICER
TENAX THERAPEUTICS, INC.   |  MUSTANG BIO, INC.
JAMES 
B 
MURPHY 
EXECUTIVE OFFICER
MUSTANG BIO, INC.
LINDSAY 
A. 
ROSENWALD 
DIRECTOR
CORONADO BIOSCIENCES INC   |  OPUS POINT HEALTHCARE INNOVATIONS FUND, L.P.   |  CB PHARMA ACQUISITION CORP.   |  CHECKPOINT THERAPEUTICS, INC.   |  HELOCYTE, INC.   |  MUSTANG BIO, INC.   |  FORTRESS BIOTECH, INC.   |  CAELUM BIOSCIENCES, INC.   |  CYPRIUM THERAPEUTICS, INC.
LINDSAY 
A. 
ROSENWALD, M.D. 
DIRECTOR
OPUS POINT HEALTHCARE INNOVATIONS (OFFSHORE) FUND LTD.   |  AVENUE THERAPEUTICS, INC.   |  URICA THERAPEUTICS, INC.   |  MUSTANG BIO, INC.
MICHAEL 
S. 
WEISS 
EXECUTIVE OFFICER, DIRECTOR
OPUS POINT HEALTHCARE INNOVATIONS FUND, L.P.   |  CB PHARMA ACQUISITION CORP.   |  OPUS POINT HEALTHCARE INNOVATIONS (OFFSHORE) FUND LTD.   |  CHECKPOINT THERAPEUTICS, INC.   |  HELOCYTE, INC.   |  MUSTANG BIO, INC.   |  FORTRESS BIOTECH, INC.   |  CAELUM BIOSCIENCES, INC.   |  URICA THERAPEUTICS, INC.
MICHAEL 
J. 
ZELEFSKY, M.D. 
DIRECTOR
MUSTANG BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-06-24
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-06-19 
2023-11-03
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2023-10-26 
2017-04-12
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2017-03-31 
2017-02-15
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2017-01-31 
2017-01-13
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-12-12 
2017-01-13
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-12-29 
2016-12-13
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-11-30 
2016-11-04
D/A
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-10-25 
2016-10-17
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2016-09-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
000000375
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NATIONAL SECURITIES CORPORATION
7569
NATIONAL SECURITIES CORPORATION
7569